Clinical Trials Logo

Clinical Trial Summary

Cough variant asthma (CVA), subtype of bronchial asthma, is considered to be one of the most common causes of chronic cough in different cough guidelines of United States, Europe, China and other countries. From a multicenter survey in China, over one third of chronic cough is caused by CVA, which is higher than western countries. CVA differs from classic asthma, usually manifesting a symptom of only coughing without wheezing or dyspnea and particularly coughing at night. With less clinical manifestation and medical intervention, CVA patients are easily be neglected and misdiagnosed, and 30-40% of them will develop to typical asthma in the next few years. Currently there's no specific therapy recommendation for CVA in GINA. Although cough guidelines in China recommend that CVA patients should be treated as typical asthma, no recommendation on details about ICS/LABA dosage and duration. There are only a few sporadic CVA therapy researches with small sample size. Two studiesfound that CVA patients can't get cough symptom relief even after treating by low dose of ICS/LABA for 3 months. Some patients' cough symptom relapses during the 24-week follow-up phase after treating by ICS/LABA for 3 months. Overall, the best treatment of CVA is not yet clear.

GINA 2018 emphasize that asthma need long-term management. Euro-SMART study found that budesonide/formoterol 2 inhalation twice daily plus as needed can reduce daytime asthma symptoms and night-time awakenings, as well as reduce exacerbation risk more than 1 inhalation twice daily. Based on the above reasons, We assume that increase the dosage of ICS/LABA can decrease relapse rate in CVA patients with severe cough. This multi-center, randomized, controlled clinical trial can help to clarify the best dosage of budesonide/formoterol of CVA in China.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04171180
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Wen Li, Prof.
Phone 86-571-87783570
Email liwenzjhz0408@163.com
Status Recruiting
Phase Phase 4
Start date May 1, 2020
Completion date May 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03319043 - Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules. Phase 1/Phase 2
Recruiting NCT03105843 - Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Mannitol Phase 4
Recruiting NCT05459805 - Multicenter Clinical Study on the Optimal Treatment Protocol and Outcome of Cough Variant Asthma With Chinese and Western Medicine N/A
Unknown status NCT02002754 - The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma Phase 4
Not yet recruiting NCT01170429 - Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA) Phase 4
Completed NCT04203472 - Optimal Type of Inhaler in Cough Variant- or Cough Predominant Asthma N/A
Recruiting NCT03169699 - Acoustic Analytic Apps for Smart Telehealth Screening - Creating a Big Data N/A
Completed NCT01064245 - Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests N/A
Completed NCT03363698 - MCT and Capsaicin Provocation Challenge in Diagnosis of Chronic Cough
Completed NCT03573284 - Validity of Fractional Exhaled Nitric Oxide and Impulse Oscillometry in Patients With Cough Variant Asthma N/A
Completed NCT00660114 - Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Children Outpatients N/A